BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 3888387)

  • 1. Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants.
    Trigg ME; Billing R; Sondel PM; Exten R; Hong R; Bozdech MJ; Horowitz SD; Finlay JL; Moen R; Longo W
    Cancer Treat Rep; 1985 Apr; 69(4):377-86. PubMed ID: 3888387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatched bone marrow transplantation in children with hematologic malignancy using T lymphocyte depleted bone marrow.
    Trigg ME; Sondel PM; Billing R; Finlay JL; Peterson A; Hong R; Frierdich S; Shahidi N
    J Biol Response Mod; 1985 Dec; 4(6):602-12. PubMed ID: 3910764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts.
    Engelhard D; Morag A; Or R; Naparstek E; Cividalli G; Ruchlemer R; Aker M; Maayan S; Slavin S
    Isr J Med Sci; 1988 Mar; 24(3):145-50. PubMed ID: 3286577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
    Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
    Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors.
    Löwenberg B; Wagemaker G; van Bekkum DW; Sizoo W; Sintnicolaas K; Hendriks WD; Hagenbeek A
    Bone Marrow Transplant; 1986 Dec; 1(2):133-40. PubMed ID: 3332128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic bone marrow transplantation in children: Tokai experience 1982 to 1984.
    Kato S; Hoshi N; Nagasaka M; Muranaka S; Yabe H; Kimura M
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):147-58. PubMed ID: 3010509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transplantation of allogeneic bone marrow treated in vitro with Campath-1 monoclonal antibody].
    Chapuis B; Helg C; Maurice P; Wyss M; Pipard G; Irlé C; Jeannet M
    Schweiz Med Wochenschr; 1985 Oct; 115(43):1521-2. PubMed ID: 3909387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse of host leukemic lymphoblasts following engraftment by an HLA-mismatched marrow transplant: mechanisms of escape from the "graft versus leukemia" effect.
    Sondel PM; Hank JA; Molenda J; Blank J; Borcherding W; Longo W; Trigg ME; Hong R; Bozdech MJ
    Exp Hematol; 1985 Sep; 13(8):782-90. PubMed ID: 2931298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cyclophosphamide and total lymphoid irradiation combined with cyclosporine in bone marrow transplantation for transfused severe aplastic anemia.
    Miyamura K; Kojima S; Takeyama K; Matsushita T; Fukuda M; Horibe K; Minami S; Morishima Y; Matsuyama K; Kodera Y
    Bone Marrow Transplant; 1988 Sep; 3(5):457-61. PubMed ID: 3056553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.
    Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Lee JS; Kim WK; Lee KH
    Bone Marrow Transplant; 2005 Apr; 35(8):755-61. PubMed ID: 15735661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion.
    Bunin N; Aplenc R; Iannone R; Leahey A; Grupp S; Monos D; Pierson G
    Bone Marrow Transplant; 2005 Feb; 35(4):369-73. PubMed ID: 15640818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb.
    Patel NC; Chinen J; Rosenblatt HM; Hanson IC; Brown BS; Paul ME; Abramson SL; Ritz J; Shearer WT
    J Allergy Clin Immunol; 2008 Dec; 122(6):1185-93. PubMed ID: 19084111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.